trial

Improving Hallucinations by Targeting the rSTS With tES

NCTId NCT05165654
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 12 (actual)
Sponsored by Beth Israel Deaconess Medical Center
Primary completion 2025-06-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2021-11-01
Primary completion
2025-06-01
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
transcranial electrical stimulation

Sponsors

Beth Israel Deaconess Medical CenterLead Sponsor

Investigators

1
Paulo Lizano, MD, PhDPrincipal Investigator

Sites

1 total
Boston, United States

Facts & assertions

4 sourced
Enrollment
12
Phase
NA
Primary Completion Date
2025-06-01
Status
COMPLETED
relationships
The graph out of here
drug
transcranial electrical stimulation
drug
lead_sponsor
Beth Israel Deaconess Medical Center
company
indication
Hallucinations
indication
Psychosis
indication
Hallucinations, Auditory
indication
investigator
Paulo Lizano, MD, PhD
person